RALEIGH, N.C., May 14, 2009 (GLOBE NEWSWIRE) -- Today DARA BioSciences, Inc. (Nasdaq:DARA) announced that the DB959 program has been identified by Cambridge Healthtech Institute (“CHI”) for inclusion in its 2nd Annual ‘Targeting Diabetes with Novel Therapeutics’ meeting. Mary Kay Delmedico, Ph.D., will present a 25 minute talk entitled “DB959: A Novel, Dual PPAR delta/gamma Agonist (DB959) for the Treatment of Type 2 Diabetes” as part of the multi-track Discovery on Target (“DOT”) Conference being held in Boston, MA, November 3-4, 2009. Additional information about the conference can be found at http://www.discoveryontarget.com.
